

ABSTRACT OF THE DISCLOSURE

The mono amine oxidase inhibitor (MAOI) hydrazide provides a new use to target and shutdown cells that host cancer and viral infections due to their incessant metastatic and disease related protein biosynthesis activity. This prodrug mechanism is provided by the hydrazide irreversible substrate ($R'NH\text{NHCOR''}$) that is targeted by protease cleavage because it simulates the amine linkage ($R'NHCOR''$) of protein substrates normally hydrolyzed by protease. Such cleavage action transfers the reactive hydrazine bond to the protease enzyme thus blocking its action which shuts down cell protein biosynthesis capability which induces cell apoptosis and replacement with a disease free cell.